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| Summary |
Background. Gestational toxoplasmosis is acquired during 
pregnancy and involves a risk of the parasite crossing the 
placenta, thereby leading to foetal infection, which can lead 
to serious sequelae in children, mainly chorioretinitis, cerebral 
calcification, hydrocephalus and intellectual disability.
Objective. Determining the prevalence of maternal and 
neonatal toxoplasmosis in women attending the Engativá 
and La Victoria hospitals in Bogota, Colombia, for delivery. 
Correlating the results with those of a national multicentre 
study. Determining IgM and IgA anti-toxoplasma prevalence 
in newborn (NB) umbilical cord blood.
Materials and methods. This was a cohort study, which was 
approved by the participating institutions’ ethics committees. 
The patients signed informed consent forms and filled out a 
survey requesting demographic and prenatal care data. A blood 
sample was taken from the umbilical cord on delivery for 
determining anti-toxoplasma IgM. Anti-toxoplasma IgA was 
also measured in a subset of patients. Children suspected of 
having either clinical or serological congenital toxoplasmosis 
were followed-up for 12 months.
Results. The study involved taking 3,224 NB umbilical 
cord blood samples between April 1st 2009 and July 16th 
2010. Positive anti-toxoplasma IgG was found in 28.2% of 
pregnant women (26.1-29.8 95%CI). Anti-toxoplasma IgM 
was determined in 558 pregnant women and found positive 
in 34 patients (i.e. 1.1 per 100 NB gestational toxoplasmosis 
incidence). Nine blood samples were positive (7 for IgM and 
2 for IgA). Five of the NB studied (0.15%) were positive for 
IgG after 12 months’ follow-up, thereby confirming a diagnosis 
of congenital toxoplasmosis accounting for 1 in every 645 
live births.
Conclusion. This study showed that 70% of the pregnant 
women were not infected with T. gondii in the chosen hospitals 
in Bogotá. Gestational toxoplasmosis frequency was around 1% 
and 0.6% for congenital toxoplasmosis.
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Resumen
Antecedentes. La toxoplasmosis gestacional es la adquisición 
de la enfermedad durante la gestación, con el riesgo de que 
el parásito atraviese la placenta and produzca una infección 
fetal, que puede llevar a importantes secuelas en el niño, 
principalmente coroidoretinitis, calcificaciones cerebrales, 
hidrocefalia and retardo mental. 
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Objetivo. Conocer la prevalencia de la toxoplasmosis materna 
and neonatal, de las mujeres que asistieron para la atención del 
parto, en los Hospitales Engativá and La Victoria, de Bogotá, 
Colombia y correlacionar los resultados con los del estudio 
multicéntrico nacional. Determinar la prevalencia de IgM and 
IgA en sangre de cordón umbilical de los recién nacidos (RN). 
Materiales and métodos. Estudio de cohorte. El estudio 
fue aprobado por los comités de ética de las instituciones. 
Las pacientes firmaron el consentimiento informado y, 
posteriormente, se les diligenció el formato de recolección 
de datos, para conocer las características demográficas 
and los datos del control prenatal. En el parto, después del 
pinzamiento del cordón, se tomó una muestra de sangre de 
este, para determinar IgM antitoxoplasma y en un subgrupo de 
pacientes también se midió la IgA antitoxoplasma. Los niños 
con datos clínicos o serológicos sospechosos de toxoplasmosis 
congénita, se siguieron hasta los 12 meses.
Resultados. Se tomaron muestras de 3.224 RN, entre el 1 
de abril de 2009 y el 16 de julio de 2010. En las gestantes 
se encontró IgG anti-Toxoplasma positiva en 28,2% 
(IC95% 26,1-29,8). Se determinó la IgM anti-Toxoplasma 
en 558 gestantes encontrando 34 positivas, calculando una 
incidencia de toxoplasmosis gestacional de 1,1 por cada 100 
RN. Se estudiaron 3215 muestras de cordón umbilical y se 
encontraron nueve casos positivos (siete con IgM y dos con 
IgA). De los RN estudiados, cinco (0,15%) tuvieron resultado 
positivo de IgG al año de edad, con lo cual se confirmó el 
diagnostico de toxoplasmosis congénita; esto equivale a un 
diagnóstico de toxoplasmosis congénita en 1 de cada 645 
nacidos vivos.
Conclusión. En este estudio se encontró que, en los hospitales 
de Bogotá estudiados, aproximadamente el 70% de las mujeres 
al momento de la gestación no se han infectado con el T. 
gondii. La frecuencia de la toxoplasmosis gestacional es de 
aproximadamente 1% y la de toxoplasmosis congénita de 0,6%.
Palabras clave: Toxoplasmosis Congénita, Embarazo, 
Prevalencia, Diagnóstico (DeCS).
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Introduction
Toxoplasma gondii is a parasite causing one of the most 
common parasitic infections in human beings. The parasite’s 
vertical transmission in pregnant women may lead to significant 
morbidity and mortality for the foetus and the newborn and 
serious consequences regarding children’s neurological and 
ophthalmological development.  
Congenital toxoplasmosis is one of the Colombian health 
plan’s priorities; it forms part of the objective aimed at 
improving children’s health. It is also part of the policy for 
implementing a congenital anomalies surveillance system, 
emphasising German measles, syphilis and toxoplasmosis. This 
study is appropriate at a time when management of the disease 
is controversial and when data is needed which will hopefully 
provide answers for resolving such controversy.
Toxoplasma gondii infection is a worldwide zoonosis. 
Prevalence varies between geographical regions and seems 
to be related to people’s eating and hygienic habits, thereby 
supporting the oral route as the most important transmission 
mechanism (1). Serological studies have shown that at least a 
third of the world’s adult population has been infected by the 
parasite (2); this means that 1,000 to 2,000 million people are 
currently infected (3). 
The largest study in Colombia concerning toxoplasmosis 
prevalence in the general population was carried out in 1982 
(the Colombian Health Study) which calculate prevalence as 
being 47% (4).  According to the study, prevalence increased 
with age and there were significant variations between regions. 
The highest prevalence was found on Colombia’s Atlantic coast 
(63%) whilst prevalence in the central region was almost half 
this (36%). The risk of acquiring the infection was calculated 
as being 1.5% in females aged 10-15 years old and fell to 0.7% 
in the 40-44 year-old group (5).
Toxoplasmosis prevalence varies greatly regarding pregnant 
women; it is around 54% in France but only 12% in Sweden 
(6). Toxoplasma gondii seroprevalence for 15 to 55 year-old 
women in the USA is 15% (7), around 35% in México and 59% 
to 78% in Brazil (São Paulo, Rio de Janeiro) (8).
Primary infection incidence during pregnancy varies greatly 
from country to country, the average varying from less than 1 
to more than 15 per 1,000 pregnancies. Incidence in European 
countries has been calculated as being 2.9 in Denmark, 3.4 
in Holland and 8.1 in France per 1,000 susceptible pregnant 
women. A study of pregnant women in Quindío, Colombia, 
found around 1.9% incidence (5, 9).
Worldwide congenital toxoplasmosis prevalence in the 
newborn may vary from 1 to 10 per 10,000 live births, 
depending on the geographical area. This has been calculated 
as being 1/10,000 live births (LB) in Sweden, 3/10,000 LB in 
Brazil and 10/10,000 LB in France (9). It has been estimated 
that this could range from 2 to 10 per 1,000 LB in Colombia, 
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representing 600 to 3,000 children born every year with 
congenital infection, 10% of whom die (i.e. 600 children 
die every year from this infection throughout Colombia, 
representing 3.7% of infant mortality in Colombia). These 
figures highlight the fact that congenital toxoplasmosis is a 
serious public health problem and represents one of the three 
main causes of prenatal infection (10). 
It has been proposed that anti-Toxoplasma IgM and IgA 
should be measured in umbilical cord blood when a baby is 
born for diagnosing congenital toxoplasmosis. Studies have 
found sensitivity ranging from 28% for the ELISA test to 91% 
for the immunosorbent agglutination assay (ISAGA) and 78% 
specificity has been found for IgM (11,12);  54% sensitivity has 
been found for IgA in cord blood and 88% specificity for the 
ISAGA IgA test in the absence of specific IgM (11, 13). It is not 
known whether there are geographical variations regarding the 
presence of specific IgA in the absence of anti-Toxoplasma IgM.
No data is available reflecting the current situation in Bogotá. 
A 1998 study reported 47% prevalence for anti-Toxoplasma IgG 
antibodies in 637 maternal sera samples and 2.2% frequency 
in recently infected patients (according to criteria requiring 
the simultaneous presence of anti-Toxoplasma IgM and IgA) 
(14). It is not known which frequency rate (data has not been 
updated since 2010) has been used in current studies concerning 
toxoplasmosis during pregnancy or how many receive treatment 
or the correlation with figures from the Colombian multicentre 
study on neonatal toxoplasmosis (15). 
This study’s main objective was to ascertain maternal 
and neonatal toxoplasmosis prevalence in two hospitals in 
Bogotá, Colombia, and correlate the results with those from 
the Colombian multicentre study (April 2009 to July 2010).  
The secondary objectives included describing this cohort 
of patients’ demographic characteristics. They also included 
describing data regarding anti-Toxoplasma IgM and IgA 
prevalence in umbilical cord blood from a representative 
group of newborn from two hospitals in Bogotá obtained 
during the Colombian multicentre study and correlating this 
with data obtained from analysing the pregnant women’s 
clinical histories. Another objective focused on ascertaining 
Toxoplasma IgG and IgM seroprevalence during pregnancy in 
the mothers of the newborn being studied. 
Materials and methods
This was a cohort study. All patients going into labour at 
both target hospitals were invited to participate (consecutively) 
until sample size had been completed.
Ethical aspects. The study was approved by Hospital 
Engativá ESE ethics committee (memorandum CERE 08, 
14th August 2009) and the Universidad del Quindío’s ethics 
committee (minute 14, 23rd June 2008). It was considered 
that this study, which involved obtaining umbilical cord 
blood samples, was a risk-free procedure and that identifying 
infection would benefit any infected child. All the women 
who agreed to participate in the study signed an informed 
consent form.
Surveys. A questionnaire was completed for each 
participant which asked for data regarding their age, level in 
the Colombian system for selecting beneficiaries for social 
(security) programmes, prenatal controls, toxoplasmosis tests 
during pregnancy, positive anti-Toxoplasma IgM test and 
diagnosis of and treatment for toxoplasmosis. 
Blood samples and laboratory tests. Blood samples were 
taken from the umbilical cord at the moment of birth. The 
hospitals’ laboratory staff centrifuged and stored the samples 
in tubes for a maximum 8 days at 4°C and then sent them 
to the reference laboratory. These sera were analysed for 
antitoxoplasma IgM by fluorometric enzyme immunocapture 
assay (Toxoplasma gondii IgM, Vircell, Grenada, Spain), 
according to the manufacturer’s indications. An IgA detection 
test was made of 10% of the samples using an immunosorbent 
agglutination assay (ISAGA, Biomerieux, Lyon, France); this 
is an immunocapture reference test which uses formolised 
toxoplasma antigen. This methodology has been described 
in in an article by Gómez (15).
Patient follow-up. All the children so identified were 
followed-up until their infection state was ascertained. 
A diagnosis of congenital toxoplasmosis was confirmed 
according to that established by the European Research 
Network on Congenital Toxoplasmosis. This included 
IgG specific antibodies persisting after 12 months of age, 
stable titres in the absence of treatment, compatible signs 
(cerebral calcification, toxoplasmic retinochoroiditis and/
or hydrocephalus) or positive anti-Toxoplasma IgG and 
IgM titres in a mother’s sera and anti-Toxoplasma IgG in a 
child’s sera (16). Children having reduced IgG titres and in 
whom anti-Toxoplasma IgG was negative in the absence of 
treatment were considered not to be infected. Treatment was 
provided based on current recommendations, i.e. sulfadiazine, 
pyrimethamine and folinic acid (5). 
Epi-Info software (CDC, Atlanta, GA, USA) was used for 
analysing the data. The results were expressed as means and 
standard deviation for continuous variables and numbers and 
percentages (N, %) for categorical variables.
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Results
Samples were collected from the participating patients 
between the 1st April 2009 and 16th July 2010 at Hospital 
Engativá (level 2) and Hospital La Victoria (at the Instituto 
Materno Infantil, level 3); 1,448 newborn at Hospital Engativá 
and 1,776 from the Instituto Materno Infantil were included 
in the study (total 3,224).
The pregnant women’s average age was 22 years old (mode 
19; range 10 to 49 years old). 
Distribution by age was as follows: 19.4% pregnant 
adolescents   (10-18 years old), 72.1% pregnant adults (19-35 
years old) and 8.4% older pregnant females (>35 years old).
Socioeconomic level was identified for 2,880 patients. 
Distribution by social strata was as follows: 35.8% in social 
level one, 43.4% in level two, 20.3% in level three, 0.5% in 
level four and 0.1% in level six. 
Regarding obstetric background, data was obtained for 
2,982 pregnant women. The average and the mode regarding 
parity was 1 birth (ranging from 1 to 10); 27.7% of the patients 
were nulliparous, 69.7% multiparous (1-4 births) and 2.6% 
were large-scale multiparous (>5 births). 17.5% had undergone 
1 abortion and 4.5% had had more than one abortion. 1.7% 
of the patients had suffered 1 or more stillbirths during their 
reproductive lives.
Concerning prenatal controls, data was obtained for 3,045 
patients; the average and mode were 5 prenatal controls 
(ranging from 0 to 20); 7.4% of the patients had not attended 
any, 64.8% had attended 1 to 6 and 27.8% of the patients had 
attended 7 or more prenatal controls. Regarding the newborn, 
the Capurro method was used for estimating gestational age 
in 2,678 of the patients; the average was 39 weeks (the same 
as the mode, ranging from 20 to 42 weeks): 0.3% were less 
than 28 weeks, 3.9% 28 to 34 weeks, 6.1% 35 to 36 weeks 
and 89.7% were more than 37 weeks old. 
Data concerning the newborn was collected for 3,087 
patients; 49.3% were female and 50.7% male. Average 
birthweight was 3,005 gr and the mode was 3,030 (ranging 
from 455 gr to 4,800 gr. Neonates were classified according 
to weight as follows:
Extremely low birthweight (ELBW) <1,000 g (0.4%); 
Very low birthweight (VLBW) 1,000–1,500 g (1.0%); 
Low bir thweight  (LBW) 1,501–2,500 g (2.2%); 
Normal birthweight (NBW) 2,500–3,500 g (85.4%); and 
Excessive birthweight (EBW) > 3,500 g (1.0%).
Clinical data regarding neonates was found in 2,843 
questionnaires.  Neither hepato-splenomegaly nor 
microcephaly was found in any newborn in the study; jaundice 
was identified in 0.4% (11 children) and macrocephaly in 
one neonate. 
Regarding obstetric echography, 96.4% of the 2.841 data 
collected recorded normal echography, only 3.6% being 
abnormal. The type of abnormality found was not specified 
in the questionnaires.
Maternal serum markers 
Data was found in 3,058 questionnaires for evaluating 
anti-Toxoplasma IgG during pregnancy. This test was made 
for 76.7% of the patients; the result was known for 2,258 
patients and positive IgG was reported for 28.2% (26.1-29.8 
95%CI) of them. 
Anti-Toxoplasma IgG seropositivity prevalence became 
increased with age, bearing in mind the patients from whom 
samples were taken and for whom the result was known, as 
follows: Adolescents (479): 17.0%, Adults (1832): 29.8%, 
Older pregnant females (232): 36.7%.
Anti-Toxoplasma IgG seropositivity prevalence according 
to socioeconomic strata was as follows: 26.5% were in social 
strata 1, 23.3% in social strata 2, 23.6% in social strata 3, 40% 
in social strata 4 and 0% in social strata 5 and 6. 
Data was obtained for 558 patients regarding anti-
Toxoplasma IgM during pregnancy; positive results were 
found for 34 patients. Gestational toxoplasmosis incidence in 
this group of patients was 1.1 per 100 NB based on calculating 
the total of pregnant women studied (3,224). It is worth noting 
that 7.5% of the patients having positive IgG did not take the 
IgM test and 18% did not claim their results.
Data regarding treatment during pregnancy was obtained 
for 2,803 patients, 29 of whom (1% of the pregnant women 
in this cohort) received treatment. 
Twenty-five (69.4%) of the 34 patients having a positive 
result received treatment; 22 received spiramycin and the 
treatment received by the other 3 was unknown.
Newborn serum markers 
An anti-Toxoplasma IgM result was obtained in cord blood 
in 3,215 patients; 7 samples were positive. Anti-Toxoplasma 
IgA was measured in a subgroup of 424 patients, 2 of them 
proving positive (Table 1).
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Tabla 1. Congenital toxoplasmosis markers.
Institution
Maternal 
history
     N       (%)
IgM + in cord 
blood 
  N      (%)   
IgA + in cord 
blood
  N     (%)
Engativa – 
La Victoria 
IMI
34/3224   (1.1)  7/3215   (0.22)     2/424     (0.47)
Fuente: autores.
Analysing the data for patients from Engativá and La 
Victoria-IMI revealed that no NB were identified as having 
positive IgM in cord blood amongst the pregnant females 
having positive IgM detected during pregnancy. The 7 NB 
having positive IgM in cord blood came from mothers having 
negative IgG during their pregnancy.  
All children having positive IgM results in umbilical cord 
blood had normal obstetric echographies. No positive IgM 
results were found in cord blood in the NBs suffering jaundice 
or in macrocephalic NB in the study.
Of the 3,224 NB recruited, those having a clinical neonatal 
maternal history or serological results giving rise to a 
suspicion of congenital toxoplasmosis were followed-up. It 
was found that 5 children (0.15%) had a positive IgG result 
regarding their year of age, thereby confirming their diagnosis 
of congenital toxoplasmosis (i.e. a diagnosis of congenital 
toxoplasmosis in 1 in 645 LB).
Discussion
This group of patients had antenatal screening for 
toxoplasmosis, IgG being measured in 77% of the pregnant 
women. The report was available for 73% of them, giving 
28.2% (26%-29% 95%CI) seroprevalence. The prevalence 
found in this study was lower than the prevalence found in 
1998 in Bogotá (43%) and that reported in Bosa (45%) (17). 
The problem regarding the prevalence obtained from clinical 
history data is that this does not allow ascertaining whether 
the techniques’ cut-off points were different, whether results 
were correctly transcribed or whether different techniques 
were used. An alternative explanation is that the population’s 
socioeconomic conditions have improved during the last 
few years and this has favoured a reduction in prevalence 
(18,19).
Analysing seroprevalence by age revealed that IgG 
seropositivity during pregnancy increased significantly with 
age. This has been described previously and may be explained 
by pregnant adolescent females’ longer exposure to infection. 
This group has increased in Colombia during the last few 
years, placing it at greater risk of congenital toxoplasmosis 
transmission and thereby aggravating the social and economic 
load of pregnancy during adolescence.  
It was found that the average week for IgG titres being 
taken was during week 20 and that for IgM during week 26, 
suggesting that the start of screening during prenatal control 
and/or controls began late, thereby hampering acute infection 
being detected during the first half of pregnancy, delaying 
opportune treatment and possibly leaving greater sequelae 
in the foetus.
Positive gestational toxoplasmosis IgM incidence in our 
study was 1.1 per 100 LB. The aforementioned national 
study found a history of toxoplasmosis during pregnancy 
in 143 questionnaires from the 15,333 cases studied (0.93 
per 100 LB) (15). Previous studies have found that 0.6% 
to 3% of pregnant women acquired the infection during 
pregnancy, that such risk was greater in adolescents who had 
1.5% probability of seroconversion and that this was lower 
for pregnant women aged 35 or more years old (0.7% risk 
of seroconversion) (20).  However, it is considered that the 
rate found in this study could have been under-reported since 
not all IgG positive patients had an IgM test and those who 
were negative did not have suitable follow-up, meaning that 
such data remained unknown and thus seroconversion rates 
could not be evaluated.    
A 61% of the patients were treated with spiramycin. The 
new Colombian Comprehensive Attention Guidelines (21) 
for maternal toxoplasmosis recommend level B treatment 
and evidence has been produced regarding the need for early 
treatment for improving treatment benefit. This data thus 
highlights the need for improving early identification and 
beginning of treatment by overcoming the administrative 
barriers preventing it. On the other hand, there was a group 
of pregnant women regarding whom no justification could be 
found for using spiramycin, thereby indicating the need for 
ongoing training in gestational toxoplasmosis management 
for improving its pertinence and effectiveness by using the 
new comprehensive attention guidelines which clarify the 
pattern to be followed when managing this infection. 
A 0.22% rate was found for anti-Toxoplasma IgM in cord 
blood, this being better than that calculated in the Colombian 
multicentre study (1.2%) (15). It is known that testing IgM 
and IgA in cord blood leads to detecting 70% of NB and that 
10 to 12 months postnatal follow-up is required for detecting 
the rest of the infected children (22). All cases should thus 
ideally be identified since pregnancy, thereby allowing the 
best benefits possible and reducing the probability of any 
child developing signs of infection. 
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One reason explaining why early serological markers were 
not detected in the NB is that they received treatment involving 
prenatal spiramycin which reduced parasitaemia and delayed 
or modulated NB immunological response (14). Regarding 
treatment, no evidence was found in our study which led to 
ascertaining its impact in avoiding infection as few cases 
were treated (i.e. not enough to demonstrate any statistically 
significant effect). 
It was found that the presence of a negative IgG in 
pregnant woman was underestimated; it was interpreted as 
no risk of toxoplasmosis, and the patient is not follow during 
the pregnancy with new determinations of IgM or IgG. or, 
even less so, warned about taking preventative measures or 
educated regarding preventative strategies.
This study’s results are relevant when it is taken into 
account that the sample size was several times greater 
than that in similar work and represents a tangible effort at 
understanding the real situation regarding toxoplasmosis in 
Bogotá. However, one of the study’s weaknesses lay in the 
loss concerning patient follow-up during all phases of the 
study.  Patients were found who had attended very few or 
no prenatal controls; only two thirds of the patients who had 
attended prenatal controls had taken an antitoxoplasma IgG 
test during pregnancy. Some patients never knew the result 
of their tests and it was not known why some did not claim 
them or why there had been a delay in making them available. 
The type of irregular screening which these patients 
received was not very useful and had very poor performance 
in the study conditions, involving as it did deficient prenatal 
control, late interpretation and contradictory maternal serum 
markers, late start to and irregular treatment as well as 
problems regarding health insurance. However, two out of 
five children in this cohort were detected in this way and no 
sequelae were found.
Conclusions
IgG seropositivity during pregnancy was seen to increase 
significantly with age, being 17% in adolescents, 29% in adult 
females and 37% in women over 35 years of age. 
Gestational toxoplasmosis incidence due to positive IgM 
titre was 1.1% per 100. Congenital toxoplasmosis incidence 
in both hospitals during this study was 0.15%. 
The detection strategy regarding gestational and congenital 
toxoplasmosis must be improved.
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